Therapeutic Potential of Orally Administered Rubiscolin-6.
delta-opioid receptor
opioid
peptide
rubiscolin
spinach
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Jun 2023
09 Jun 2023
Historique:
received:
29
04
2023
revised:
07
06
2023
accepted:
08
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Rubiscolins are naturally occurring opioid peptides derived from the enzymatic digestion of the ribulose bisphosphate carboxylase/oxygenase protein in spinach leaves. They are classified into two subtypes based on amino acid sequence, namely rubiscolin-5 and rubiscolin-6. In vitro studies have determined rubiscolins as G protein-biased delta-opioid receptor agonists, and in vivo studies have demonstrated that they exert several beneficial effects via the central nervous system. The most unique and attractive advantage of rubiscolin-6 over other oligopeptides is its oral availability. Therefore, it can be considered a promising candidate for the development of a novel and safe drug. In this review, we show the therapeutic potential of rubiscolin-6, mainly focusing on its effects when orally administered based on available evidence. Additionally, we present a hypothesis for the pharmacokinetics of rubiscolin-6, focusing on its absorption in the intestinal tract and ability to cross the blood-brain barrier.
Identifiants
pubmed: 37373107
pii: ijms24129959
doi: 10.3390/ijms24129959
pmc: PMC10298254
pii:
doi:
Substances chimiques
rubiscolin 6
0
Ribulose-Bisphosphate Carboxylase
EC 4.1.1.39
Receptors, Opioid, delta
0
Oligopeptides
0
Opioid Peptides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP21K08924
Organisme : Japan Society for the Promotion of Science
ID : JP21K06584
Références
Peptides. 1990 May-Jun;11(3):591-4
pubmed: 2166280
Pain. 2011 Dec;152(12):2836-2843
pubmed: 22019149
Behav Brain Res. 2018 Jan 15;336:77-84
pubmed: 28864205
Eur J Pharmacol. 2001 Jun 8;421(2):115-9
pubmed: 11399267
Handb Exp Pharmacol. 2022;271:197-220
pubmed: 34463847
Mol Nutr Food Res. 2014 Oct;58(10):2046-52
pubmed: 25047666
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Adv Alcohol Subst Abuse. 1990;9(1-2):103-28
pubmed: 1974120
J Agric Food Chem. 2007 Oct 3;55(20):8101-4
pubmed: 17803260
Curr Med Chem. 2022;29(23):4026-4049
pubmed: 34961454
Curr Pharm Des. 2010;16(9):1126-35
pubmed: 20030621
Front Cell Neurosci. 2021 Sep 16;15:745178
pubmed: 34602984
Clin J Pain. 2010 Jan;26 Suppl 10:S10-5
pubmed: 20026960
Peptides. 2003 Feb;24(2):325-8
pubmed: 12668220
Nat Genet. 2000 Jun;25(2):195-200
pubmed: 10835636
Methods Find Exp Clin Pharmacol. 1998 Sep;20(7):595-9
pubmed: 9819804
J Pharmacol Exp Ther. 2017 Jun;361(3):341-348
pubmed: 28302862
Nutr Neurosci. 2022 Jul;25(7):1413-1424
pubmed: 33373270
Biomolecules. 2022 Sep 05;12(9):
pubmed: 36139079
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):413-20
pubmed: 19643969
FEBS Lett. 2001 Dec 7;509(2):213-7
pubmed: 11741591
Am J Physiol Regul Integr Comp Physiol. 2014 Feb 15;306(4):R265-72
pubmed: 24401991
Drug Dev Res. 2021 Nov;82(7):927-944
pubmed: 33988872
Mol Nutr Food Res. 2012 Aug;56(8):1315-23
pubmed: 22715053
Signal Transduct Target Ther. 2022 Feb 14;7(1):48
pubmed: 35165272
Curr Pharm Des. 2003;9(16):1325-30
pubmed: 12769740
Brain Struct Funct. 2017 Mar;222(2):1007-1026
pubmed: 27376372
Am J Physiol Cell Physiol. 2011 Jun;300(6):C1260-9
pubmed: 21307350
Peptides. 2003 Apr;24(4):503-8
pubmed: 12860192
Pain Physician. 2008 Mar;11(2 Suppl):S105-20
pubmed: 18443635
Pharmaceuticals (Basel). 2022 Jul 15;15(7):
pubmed: 35890173
Trends Pharmacol Sci. 2011 Oct;32(10):581-90
pubmed: 21925742
Jpn J Pharmacol. 2000 Nov;84(3):259-65
pubmed: 11138726
Pain. 2008 Jun;136(3):380-387
pubmed: 17888574
Eur J Pharmacol. 1997 Oct 29;338(1):1-6
pubmed: 9407996
Curr Top Behav Neurosci. 2017;33:137-156
pubmed: 27909992
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:143-159
pubmed: 28968188
J Neurosci Res. 2022 Jan;100(1):129-148
pubmed: 32623788
Mini Rev Med Chem. 2018;18(2):104-112
pubmed: 28462718
Mol Pain. 2016 Sep 02;12:
pubmed: 27590071
Int J Cosmet Sci. 2015 Aug;37(4):386-94
pubmed: 25660727
Annu Rev Nutr. 1996;16:99-119
pubmed: 8839921
Int J Mol Sci. 2021 Aug 06;22(16):
pubmed: 34445197
Food Chem. 2021 Feb 1;337:127765
pubmed: 32799161
Brain Res. 1999 Aug 28;839(2):336-40
pubmed: 10519058
Crit Rev Oncol Hematol. 2016 Mar;99:241-8
pubmed: 26806145
J Nutr Sci Vitaminol (Tokyo). 2019;65(2):202-204
pubmed: 31061291
J Food Drug Anal. 2019 Jan;27(1):266-274
pubmed: 30648580
Pain. 2016 Aug;157(8):1588-1589
pubmed: 27428892
Am J Physiol. 1990 Jul;259(1 Pt 1):E1-10
pubmed: 2196819
F1000Res. 2017 Feb 7;6:113
pubmed: 28232867
Cell Metab. 2021 Apr 6;33(4):705-706
pubmed: 33826913
J Pharm Sci. 2012 Jan;101(1):154-63
pubmed: 21905028
Food Chem X. 2023 Mar 13;18:100640
pubmed: 37008720
Peptides. 2007 Oct;28(10):1998-2003
pubmed: 17766012
Anesth Analg. 2005 Sep;101(3):728-734
pubmed: 16115983
BMC Neurol. 2009 Jun 12;9 Suppl 1:S3
pubmed: 19534732
Pain Physician. 2008 Mar;11(2 Suppl):S133-53
pubmed: 18443637
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4738-4743
pubmed: 30782794
AAPS J. 2006 Feb 24;8(1):E76-88
pubmed: 16584136
Risk Manag Healthc Policy. 2019 Feb 14;12:23-30
pubmed: 30858741
Ageing Res Rev. 2022 Jun;78:101617
pubmed: 35378297
Handb Exp Pharmacol. 2018;247:3-19
pubmed: 27787711
Molecules. 2021 Oct 08;26(19):
pubmed: 34641621
Br J Pharmacol. 2016 Jan;173(2):332-43
pubmed: 26507558
Psychopharmacology (Berl). 2016 Mar;233(6):1119-30
pubmed: 26728893
Synapse. 2004 Nov;54(2):72-82
pubmed: 15352132